Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp.~* Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the full balding scalp~Exclusion Criteria:~* Location of the treatment area~  * within 5 cm of an incompletely healed wound~ * within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~* Prior treatment with ingenol mebutate gel on the treatment area~* Lesions in the treatment areas that have~  * atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or~ * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: LEO 43204 (Type: OTHER): Open-label, dose escalation, 2 days treatment
- Part 2: LEO 43204 x dose (Type: ACTIVE_COMPARATOR): X dose for 2 days treatment
- Part 2: LEO 43204 Y dose (Type: ACTIVE_COMPARATOR): Y dose for 2 days treatment
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Placebo for 2 days treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).